Biotech Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Little-known Novellus is licensing the drug, currently in phase 1/2 tests with Daiichi’s wholly owned biotech Plexxikon. Details are thin, but PLX8394 is being trialed in “advanced, unresectable solid tumors,” although exact target(s) were not specified in the joint statement. It’s now looking to enroll more patients into its ongoing study.